A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
Study Details
Study Description
Brief Summary
This is a Phase 1, open-label, multicenter study evaluating the safety and PK profile of
ABT-199 under a once daily dosing schedule. Two arms will be implemented for dose escalation:
Arm A, CLL/SLL subjects and Arm B, NHL subjects. Arm A is designed to enroll approximately 116 subjects with relapsed or refractory CLL or SLL and Arm B is designed to enroll approximately 95 subjects with relapsed or refractory NHL. Fifty-six subjects were enrolled in Arm A and approximately 55 subjects will be enrolled in Arm B during the dose escalation portion of the study, with the objective of defining dose limiting toxicities (DLTs) and the MTD. Once the MTD is declared for the arm, approximately 60 additional CLL/SLL subjects in Arm A and approximately 20 additional DLBCL subjects and 20 additional follicular lymphoma subjects in Arm B will be enrolled in an expanded safety portion of the study at the recommended phase 2 dose (RPTD) and schedule.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
Interventional Study Design - Primary Purpose: Determination of safety and tolerability.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm A (CLL/SLL subjects) Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) subjects |
Drug: ABT-199
Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
|
| Experimental: Arm B (NHL subjects) Non-Hodgkin lymphoma (NHL) subjects |
Drug: ABT-199
Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
|
Outcome Measures
Primary Outcome Measures
- Determination of dose limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase two dose (RPTD), and lead-in period regimen [Lead-in period (2-5 weeks) plus 3 weeks of study drug administration at the designated cohort dose (continuous dosing)]
Protocol-defined events, which can not be attributed by the investigator to a clearly identifiable cause such as tumor progression, underlying illness, concurrent illness, or concomitant medication, will be considered a DLT. Dose limiting toxicities of tumor lysis syndrome observed during the lead-in period will be attributed to the lead-in period.
- Number of subjects with adverse events [First 16 weeks of study drug administration and every 4 weeks thereafter (continuous dosing for an anticipated maximum duration of 9 months)]
- Determination of plasma peak concentration (Cmax) of ABT-199 [Up to Week 24 for ABT-199]
Blood and urine samples for pharmacokinetic analysis of ABT-199 will be collected at designated time points
- Determination of trough concentration (Ctrough) of ABT-199 [Up to Week 24 for ABT-199]
Blood and urine samples for pharmacokinetic analysis of ABT-199 will be collected at designated time points
- Determination of area under the concentration versus time curve (AUC) of ABT-199 [Up to Week 24 for ABT-199]
Blood and urine samples for pharmacokinetic analysis of ABT-199 will be collected at designated time points
Secondary Outcome Measures
- Food Effect - Cmax [Approximately 3 days]
Pharmacokinetic (PK) parameter Cmax (maximum plasma concentration of ABT-199) between each diet (ABT-199 under fasting versus low-fat, and fasting versus high-fat conditions (Cohorts 1-6 in Arm B subjects only)
- Preliminary efficacy assessment [Starting Week 4 for clinical disease progression and Week 6 for tumor response; and every 4 weeks thereafter (continuous dosing for an anticipated maximum duration of 9 months)]
Tumor response or clinical disease progression
- Minimal residual disease collection (MRD) [At least 2 months after the CR, CRi criteria for tumor response are first met. Every 12 weeks thereafter, until MRD negativity has been achieved (in peripheral blood).]
MRD assessed in the peripheral blood and/or bone marrow (BM) either by four color flow cytometry or ASO-PCR, will be measured in CLL subjects achieving CR/CRi.
- Food Effect - Tmax [Approximately 3 days]
Pharmacokinetic (PK) parameter Tmax (time to reach maximum plasma concentration of ABT-199) between each diet (ABT-199 under fasting versus low-fat, and fasting versus high-fat conditions (Cohorts 1-6 in Arm B subjects only)
- Food Effect - AUC [Approximately 3 days]
Pharmacokinetic (PK) parameter AUC (area under the concentration-time curve from time zero to hour 24 of ABT-199) between each diet (ABT-199 under fasting versus low-fat, and fasting versus high-fat conditions (Cohorts 1-6 in Arm B subjects only)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject must have either:
-
(Arm A) relapsed or refractory CLL/SLL and require treatment in the opinion of the Investigator. Subject must have relapsed following or be refractory to standard treatments such as fludarabine based regimens (F, FC, FR, FCR) or alkylator (chlorambucil, bendamustine) based regimens. In addition, there are no other curative options, and the subject has exhausted options that would be considered standard of care, or
-
(Arm B) relapsed or refractory NHL and require treatment in the opinion of the Investigator. Subject must have histologically documented diagnosis of NHL as defined in the World Health Organization classification scheme, except as noted in the exclusion criteria. Subject must have relapsed following or be refractory to standard treatments such as R-CHOP, R-CVP, or fludarabine based regimens. In addition, there are no other curative options, and the subject has exhausted options that would be considered standard of care. Subjects with other lymphoproliferative diseases can be considered in consultation with the Abbott medical monitor.
-
Subject has an Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1.
-
Subject must have adequate bone marrow independent of growth factor support per local laboratory reference range at Screening.
-
Subject must have adequate coagulation, renal, and hepatic function, per laboratory reference range at Screening.
Exclusion Criteria:
-
CLL subject has undergone an allogeneic or autologous stem cell transplant or NHL subject has undergone an allogeneic stem cell transplant or has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia.
-
Subject has tested positive for HIV.
-
Subject has a cardiovascular disability status of New York Heart Association Class greater or equal to 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity, results in fatigue, palpitations, dyspnea or anginal pain.
-
Subject has a significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study.
-
Subject has received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of Arizona Cancer Center - North Campus /ID# 52902 | Tucson | Arizona | United States | 85719-1478 |
| 2 | Ucsd /Id# 48325 | La Jolla | California | United States | 92093 |
| 3 | Dana-Farber Cancer Institute /ID# 48324 | Boston | Massachusetts | United States | 02215 |
| 4 | Memorial Sloan Kettering Cancer Center /ID# 56810 | New York | New York | United States | 10065-6007 |
| 5 | University of Texas MD Anderson Cancer Center /ID# 48326 | Houston | Texas | United States | 77030 |
| 6 | Swedish Medical Center /ID# 135853 | Seattle | Washington | United States | 98104 |
| 7 | Fred Hutchinson Cancer Research /ID# 52882 | Seattle | Washington | United States | 98109 |
| 8 | Univ of Wisconsin Hosp/Clinics /ID# 56811 | Madison | Wisconsin | United States | 53792-0001 |
| 9 | Peter MacCallum Cancer Ctr /ID# 48323 | Melbourne | Victoria | Australia | 3000 |
| 10 | Royal Melbourne Hospital /ID# 48322 | Parkville | Victoria | Australia | 3050 |
Sponsors and Collaborators
- AbbVie
- Genentech, Inc.
Investigators
- Study Director: AbbVie Inc., AbbVie
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- M12-175